Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.90 and traded as low as $7.10. Arcturus Therapeutics shares last traded at $7.72, with a volume of 907,435 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have recently commented on ARCT. Piper Sandler decreased their price objective on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Roth Mkm assumed coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 target price for the company. Finally, Citigroup lowered their price target on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Arcturus Therapeutics Trading Up 11.9%

The business’s 50 day simple moving average is $7.36 and its two-hundred day simple moving average is $9.90. The firm has a market capitalization of $219.43 million, a PE ratio of -3.24 and a beta of 2.40.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.11). Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%.The firm had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ARCT. ARK Investment Management LLC raised its stake in Arcturus Therapeutics by 39.4% during the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after acquiring an additional 738,378 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Arcturus Therapeutics by 4.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock valued at $12,423,000 after acquiring an additional 78,753 shares during the last quarter. Amova Asset Management Americas Inc. increased its holdings in shares of Arcturus Therapeutics by 4.0% in the fourth quarter. Amova Asset Management Americas Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,403,000 after purchasing an additional 78,753 shares during the last quarter. Vanguard Group Inc. increased its stake in Arcturus Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after acquiring an additional 75,440 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.